C
Cheng E. Chee
Researcher at Mayo Clinic
Publications - 29
Citations - 1235
Cheng E. Chee is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 3 publications receiving 1108 citations.
Papers
More filters
Journal ArticleDOI
The role of autophagy in cancer: therapeutic implications.
TL;DR: The role of autophagy and its regulation in cancer cells continues to emerge, and studies aim to define optimal strategies to modulate Autophagy for therapeutic advantage.
Journal ArticleDOI
Autophagy modulation for cancer therapy
TL;DR: Inhibition of cytoprotective autophagy by genetic or pharmacological means has been shown to enhance anticancer drug-induced cell death, suggesting a novel therapeutic strategy.
Journal ArticleDOI
Targeted Therapeutic Agents for Colorectal Cancer
Cheng E. Chee,Frank A. Sinicrope +1 more
TL;DR: In contrast to the results for advanced CRC, targeted therapies have not shown a benefit in the adjuvant setting for patients with resected colon cancer, and a focus on the use of targeted therapy is provided.
Journal ArticleDOI
Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors
Jhin Jieh Lim,Lissa Hooi,Yock Young Dan,Glenn Kunnath Bonney,Lei Zhou,Pierce K. H. Chow,Cheng E. Chee,Tan Boon Toh,Edward Kai-Hua Chow +8 more
TL;DR: In this paper , a hybrid experimental-computational approach, Quadratic Phenotypic Optimization Platform (QPOP), was used to identify effective proteasome inhibitor-based drug combinations.
Journal ArticleDOI
PRECISE CURATE.AI: A prospective feasibility trial to dynamically modulate personalized chemotherapy dose with artificial intelligence.
Agata Blasiak,Anh T. L. Truong,Wen Jeit, Lester Tan,Kirthika Senthil Kumar,S. Tan,Chong Boon Teo,Benjamin K.J. Tan,Xavier Costa Tadeo,Hon Lyn Tan,Cheng E. Chee,Wei Peng Yong,Dean Ho,Raghav Sundar +12 more
TL;DR: CURATE.AI has been successfully incorporated into the clinical workflow of dynamic dose selection in the treatment of solid tumors under a clinical trial and may eventually play an important role in improving patient response rates and durations compared to SOC.